| pubmed-article:19520688 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19520688 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19520688 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:19520688 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:19520688 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:19520688 | lifeskim:mentions | umls-concept:C1518965 | lld:lifeskim |
| pubmed-article:19520688 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:19520688 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:19520688 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:19520688 | pubmed:dateCreated | 2009-8-28 | lld:pubmed |
| pubmed-article:19520688 | pubmed:abstractText | The aim of this study was to determine the maximum-tolerated dose (MTD) and the recommended dose of combination chemotherapy with gemcitabine (GEM) and carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients with a performance status (PS) of 2. | lld:pubmed |
| pubmed-article:19520688 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19520688 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19520688 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19520688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19520688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19520688 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19520688 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19520688 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:19520688 | pubmed:issn | 1465-3621 | lld:pubmed |
| pubmed-article:19520688 | pubmed:author | pubmed-author:NishiwakiYuta... | lld:pubmed |
| pubmed-article:19520688 | pubmed:author | pubmed-author:SaijoNagahiro... | lld:pubmed |
| pubmed-article:19520688 | pubmed:author | pubmed-author:NihoSeijiS | lld:pubmed |
| pubmed-article:19520688 | pubmed:author | pubmed-author:KubotaKaoruK | lld:pubmed |
| pubmed-article:19520688 | pubmed:author | pubmed-author:OhmatsuHirono... | lld:pubmed |
| pubmed-article:19520688 | pubmed:author | pubmed-author:GotoKoichiK | lld:pubmed |
| pubmed-article:19520688 | pubmed:author | pubmed-author:YohKiyotakaK | lld:pubmed |
| pubmed-article:19520688 | pubmed:author | pubmed-author:KimYoung... | lld:pubmed |
| pubmed-article:19520688 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19520688 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:19520688 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19520688 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19520688 | pubmed:pagination | 576-81 | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:meshHeading | pubmed-meshheading:19520688... | lld:pubmed |
| pubmed-article:19520688 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19520688 | pubmed:articleTitle | A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2. | lld:pubmed |
| pubmed-article:19520688 | pubmed:affiliation | Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. ekim@kuhp.kyoto-u.ac.jp | lld:pubmed |
| pubmed-article:19520688 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19520688 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19520688 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
